Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003-2022.
Streptococcus pneumoniae
10-valent pneumococcal conjugate vaccine
Children under five
Pneumococcal meningitis
Uganda
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
14
08
2024
accepted:
09
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Pneumococcal meningitis, a vaccine-preventable disease caused by Streptococcus pneumoniae (Spn) is the leading bacterial meningitis in under five children. In April 2014, Uganda introduced routine immunization with 10-valent Pneumococcal Conjugate Vaccine (PCV10) for infants. The target coverage for herd immunity is ≥ 90% with three doses (PCV10-dose 3). We assessed the effect of PCV10 introduction and coverage on the trends of pneumococcal meningitis in under five children. We analyzed laboratory-confirmed pediatric bacterial meningitis (PBM) data at two high-volume WHO-accredited sentinel surveillance hospitals in Kampala City and Gulu District, from 2003 to 2022. We used confirmed cases to estimate the minimum incidence of pneumococcal meningitis in the host districts and calculated annual incidence of pneumococcal meningitis per one million populations, and the proportion of confirmed PBM attributable to Spn. We divided the study period into 2003-2013 (pre-PCV10) and 2014-2022 (post-PCV10), and conducted interrupted time series analysis using autoregressive integrated moving average models for the effect of PCV10 on trends of pneumococcal meningitis and PBM attributable to Spn. We analyzed reported PCV10 data in DHIS2 from 2014 to 2022 for annual PCV10-dose 3 coverage. Among the 534 confirmed PBM cases, 331(62%) were pneumococcal meningitis; 227(69%) from Gulu District and 104(31%) from Kampala City. The majority (95%) of the isolates were not serotyped. The majority (57%) were male and unimmunized (98%); median age = 14(IQR = 6-27) months with most (55%) aged ≥ 12 months. The case-fatality rate was 9%. During Pre-PCV10 period, the overall incidence of pneumococcal meningitis in the host districts increased; slope change = 1.0 (95%CI = 0.99999, 1.00001) but declined in post-PCV10 period (2014-2022) by 92% from 86 cases /1,000,000 in 2014 to 7/1,000,000 in 2022, slope change= -1.00006 (95%CI=-1.00033, -0.99979). Whereas there was an immediate decline in the proportion of confirmed PBM attributable to Spn in the host districts, level change=-1.84611(95%CI=-1.98365,-1.70856), an upward trend was recorded from 2016 to 2022, slope change = 1.0 (95%CI = 0.99997, 1.00003). During 2015-2022, PCV10-dose 3 coverage was largely > 90% for Gulu District and 52-72% for Kampala City. The PCV10 routine immunization program reduced the incidence of pneumococcal meningitis in Kampala City and Gulu District. There was no effect on the confirmed PBM proportionately attributable to Spn. Kampala City persistently recorded PCV10-dose3 coverage < 90%. We recommend enhancing serotyping and periodic nasopharyngeal carriage surveys to ascertain the maximum vaccine effectiveness and monitor Spn serotypes, and strengthening routine immunization in Kampala City.
Sections du résumé
BACKGROUND
BACKGROUND
Pneumococcal meningitis, a vaccine-preventable disease caused by Streptococcus pneumoniae (Spn) is the leading bacterial meningitis in under five children. In April 2014, Uganda introduced routine immunization with 10-valent Pneumococcal Conjugate Vaccine (PCV10) for infants. The target coverage for herd immunity is ≥ 90% with three doses (PCV10-dose 3). We assessed the effect of PCV10 introduction and coverage on the trends of pneumococcal meningitis in under five children.
METHODS
METHODS
We analyzed laboratory-confirmed pediatric bacterial meningitis (PBM) data at two high-volume WHO-accredited sentinel surveillance hospitals in Kampala City and Gulu District, from 2003 to 2022. We used confirmed cases to estimate the minimum incidence of pneumococcal meningitis in the host districts and calculated annual incidence of pneumococcal meningitis per one million populations, and the proportion of confirmed PBM attributable to Spn. We divided the study period into 2003-2013 (pre-PCV10) and 2014-2022 (post-PCV10), and conducted interrupted time series analysis using autoregressive integrated moving average models for the effect of PCV10 on trends of pneumococcal meningitis and PBM attributable to Spn. We analyzed reported PCV10 data in DHIS2 from 2014 to 2022 for annual PCV10-dose 3 coverage.
RESULTS
RESULTS
Among the 534 confirmed PBM cases, 331(62%) were pneumococcal meningitis; 227(69%) from Gulu District and 104(31%) from Kampala City. The majority (95%) of the isolates were not serotyped. The majority (57%) were male and unimmunized (98%); median age = 14(IQR = 6-27) months with most (55%) aged ≥ 12 months. The case-fatality rate was 9%. During Pre-PCV10 period, the overall incidence of pneumococcal meningitis in the host districts increased; slope change = 1.0 (95%CI = 0.99999, 1.00001) but declined in post-PCV10 period (2014-2022) by 92% from 86 cases /1,000,000 in 2014 to 7/1,000,000 in 2022, slope change= -1.00006 (95%CI=-1.00033, -0.99979). Whereas there was an immediate decline in the proportion of confirmed PBM attributable to Spn in the host districts, level change=-1.84611(95%CI=-1.98365,-1.70856), an upward trend was recorded from 2016 to 2022, slope change = 1.0 (95%CI = 0.99997, 1.00003). During 2015-2022, PCV10-dose 3 coverage was largely > 90% for Gulu District and 52-72% for Kampala City.
CONCLUSION
CONCLUSIONS
The PCV10 routine immunization program reduced the incidence of pneumococcal meningitis in Kampala City and Gulu District. There was no effect on the confirmed PBM proportionately attributable to Spn. Kampala City persistently recorded PCV10-dose3 coverage < 90%. We recommend enhancing serotyping and periodic nasopharyngeal carriage surveys to ascertain the maximum vaccine effectiveness and monitor Spn serotypes, and strengthening routine immunization in Kampala City.
Identifiants
pubmed: 39434021
doi: 10.1186/s12879-024-10075-y
pii: 10.1186/s12879-024-10075-y
doi:
Substances chimiques
Pneumococcal Vaccines
0
10-valent pneumococcal conjugate vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1187Subventions
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Organisme : President's Emergency Plan for AIDS (PEPFAR) through the United States Centers for Disease Control and Prevention Cooperative Agreement number GH001353-01 through the Makerere University School of Public Health to the Uganda Public Health Fellowship Program, Ministry of Health
ID : GH001353-01
Informations de copyright
© 2024. The Author(s).
Références
mondiale de la Santé O, Organization WH. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper–February 2019 Vaccins antipneumococciques conjugués chez les nourrissons et les enfants de moins de 5 ans: note de synthèse de l’OMS–février 2019. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. 2019;94(08):85–103.
WHO, Pneumococcal Disease. 2023. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease
WHO. Pneumococcal meningitis-Togo 2023 [updated 11-4-2023]. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON455
Oligbu G, Collins S, Sheppard CL, Fry NK, Slack M, Borrow R, et al. Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006–2014. Clin Infect Dis. 2017;65(2):308–14.
doi: 10.1093/cid/cix310
pubmed: 28605414
Mwenda JM, Soda E, Weldegebriel G, Katsande R, Biey JN-M, Traore T, et al. Pediatric bacterial meningitis surveillance in the World Health Organization African region using the invasive bacterial vaccine-preventable disease surveillance network, 2011–2016. Clin Infect Dis. 2019;69(Supplement2):S49–57.
doi: 10.1093/cid/ciz472
pubmed: 31505629
pmcid: 6736400
Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019;393(10186):2146–54.
doi: 10.1016/S0140-6736(18)33005-8
pubmed: 31000194
pmcid: 6548991
Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in the Gambia: a population-based surveillance study. Lancet Infect Dis. 2016;16(6):703–11.
doi: 10.1016/S1473-3099(16)00054-2
pubmed: 26897105
pmcid: 4909992
Kisakye A, Makumbi I, Nansera D, Lewis R, Braka F, Wobudeya E, et al. Surveillance for Streptococcus pneumoniae meningitis in children aged < 5 years: implications for immunization in Uganda. Clin Infect Dis. 2009;48(Supplement2):S153–61.
doi: 10.1086/596495
pubmed: 19191611
UNEPI. Immunization guidelines 2022. https://www.health.go.ug/wp-content/uploads/2019/11/UNEPI-Immunization-guidelines.pdf
Health Mo. 2023 [updated 15-6-2023]. https://hmis.health.go.ug/dhis-web-data-visualizer/index.html#/
Immunization WHODo. Immunization in practice: a practical guide for health staff. World Health Organization; 2015.
Swarthout TD, Henrion MY, Thindwa D, Meiring JE, Mbewe M, Kalizang’Oma A, et al. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study. Lancet Infect Dis. 2022;22(12):1737–47.
doi: 10.1016/S1473-3099(22)00438-8
pubmed: 36029796
pmcid: 10555849
Organization WH. Overview of VPD surveillance principles 2018 [cited 2023 August 2023]. https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/vpd-surveillance-standards-publication/who-surveillancevaccinepreventable-01-overview-r2.pdf?sfvrsn=932d9e08_8&download=true
Health UMo. Coverage for key antigens 2023. https://hmis.health.go.ug/dhis-web-dashboard/#/
Statistics UBo, Population, Censuses. 2023. https://www.ubos.org/explore-statistics/20/
Tagbo BN, Bancroft RE, Fajolu I, Abdulkadir MB, Bashir MF, Okunola OP, et al. Pediatric bacterial meningitis surveillance in Nigeria from 2010 to 2016, prior to and during the phased introduction of the 10-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2019;69(Supplement2):S81–8.
doi: 10.1093/cid/ciz474
pubmed: 31505626
pmcid: 6736152
UNICEF Wa. Uganda: WHO and UNICEF estimates of immunization coverage: 2022 revision 2023. https://www.google.com/search?q=Uganda%3A+WHO+and+UNICEF+estimates+of+immunization+coverage%3A+2022+revision&oq=Uganda%3A+WHO+and+UNICEF+estimates+of+immunization+coverage%3A+2022+revision&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRg6MgYIAhBFGDzSAQgxMzk5ajBqN6gCALACAA&sourceid=chrome&ie=UTF-8
Organization WH. Immunization in practice: a practical guide for health staff, 2015 update 2015. https://iris.who.int/handle/10665/193412
Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 2014;33(5):504–10.
doi: 10.1097/INF.0000000000000279
pubmed: 24670957
Ali I. Impact of COVID-19 on vaccination programs: adverse or positive? Hum Vaccines Immunotherapeutics. 2020;16(11):2594–600.
doi: 10.1080/21645515.2020.1787065
Lassi ZS, Naseem R, Salam RA, Siddiqui F, Das JK. The impact of the COVID-19 pandemic on immunization campaigns and programs: a systematic review. Int J Environ Res Public Health. 2021;18(3):988.
doi: 10.3390/ijerph18030988
pubmed: 33499422
pmcid: 7908591